新的低剂量三重单片药组合治疗高血压的理由
Anthony Rodgers1, Abdul Salam2,3, William Cushman4
1The George Institute for Global Health, University of New South Wales, Australia.
Global heart
|February 19, 2024
概括
对高血压的单片药物组合有希望,可以实现高血压的控制,而不会增加副作用. 新的三重疗法多药正在开发中,以解决有效高血压管理的未满足需求.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 单一药丸组合 (SPC) 与多个低剂量成分已经证明在高血压管理中的有效性.
- 现有的SPC显示优于血压控制的通常护理 (>80%),没有增加副作用.
- 对于临床使用这种三元组合SPC的可用性存在差距.
研究的目的:
- 引入GMRx2,一种用于高血压治疗的新型单片药物组合 (SPC).
- 为了支持对GMRx2的监管提交 (FDA),包括高血压的初始治疗.
- 评估GMRx2与安慰剂和双组分组合的疗效和安全性.
主要方法:
- 开发的GMRx2含有telmisartan/amlodipine/indapamide的三种固定剂量强度.
- 目前正在进行的关键试验评估GMRx2.2的有效性和安全性.
- 将GMRx2与安慰剂以及其组件的所有可能的双重组合进行比较.
主要成果:
- 两项大型试验证明了SPC具有≥3个低剂量组件的高血压的潜力.
- 这些"高血压多重药"与通常护理相比,实现了>80%的血压控制.
- 在之前的试验中,没有观察到因副作用而导致戒断的增加.
结论:
- GMRx2解决了对高血压三组合SPC的未满足需求.
- 计划于2024年提交的监管文件旨在使GMRx2在全球范围内可访问.
- 进一步的研究将指导基于GMRx2的治疗策略的实施和扩展.
相关概念视频
01:01Dosage Regimen: Fixed Dose
1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
01:23Antihypertensive Drugs: Vasodilators
524
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
524
01:25Antihypertensive Drugs: Direct Renin Inhibitors
629
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
629
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
635
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
635